Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 3/20 | 0.54 |
| ▸ | LCK | P06239 | 1/20 | 0.54 |
| ▸ | FYN | P06241 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | CA4 | P22748 | 2/20 | 0.35 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL7309563 | 0.96 | — | — | |
| Acetic Acid SCHEMBL59820 | 0.96 | — | — | |
| Acetic Acid SCHEMBL10743699 | 0.96 | FFAR3 (0.58) | FFAR3LCKFYNTSHRLMNA | |
| Acetic Acid SCHEMBL10386503 | 0.96 | FFAR3 (0.58) | FFAR3LCKFYNTSHRLMNA | |
| Acetic Acid SCHEMBL28661347 | 0.92 | FFAR3 (0.54) | FFAR3LCKFYNTSHRLMNA | |
| Acetic Acid SCHEMBL17768458 | 0.92 | FFAR3 (0.54) | FFAR3LCKFYNTSHRLMNA | |
| Acetic Acid SCHEMBL28343178 | 0.92 | FFAR3 (0.64) | FFAR3LCKFYNTSHRLMNA | |
| Acetic Acid SCHEMBL282406 | 0.92 | — | — | |
| Acetic Acid SCHEMBL5035361 | 0.92 | — | — | |
| Acetic Acid SCHEMBL2706810 | 0.92 | FFAR3 (0.64) | FFAR3LCKFYNTSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110297063-A | A kind of quality determining method of Rhizoma Chuanxiong hair washing water extract | 四川绿色本草科技发展有限公司 | 2019-10-01 | — | — | CN | claimed |
| CN-115792075-B | Detection method of 4' -monophosphoryl lipid A compound | 江苏瑞科生物技术股份有限公司 | 2023-11-03 | — | — | CN | disclosed |
| CN-115792075-A | Detection method of 4' -monophosphoryl lipid A compound | 江苏瑞科生物技术股份有限公司 | 2023-03-14 | — | — | CN | disclosed |
| US-9364556-B2 | Drug conjugate comprising drug linked to human c-Met antibody, and use therefor | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2016-06-14 | — | — | US | disclosed |
| US-20150110815-A1 | DRUG CONJUGATE COMPRISING DRUG LINKED TO HUMAN C-MET ANTIBODY, AND USE THEREFOR | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2015-04-23 | — | — | US | disclosed |
| US-8765766-B2 | Pyrimidine derivatives which are antagonists of the vitronectin receptor | GALAPAGOS NV (BE) | 2014-07-01 | — | — | US | disclosed |
| US-20120316338-A1 | Methods and Intermediates for the Preparation of Optionally Radio-Labeled Imatinib | SALTER RHYS (CH) | 2012-12-13 | — | — | US | disclosed |
| US-20120115883-A1 | PYRIMIDINE DERIVATIVES WHICH ARE ANTAGONISTS OF THE VITRONECTIN RECEPTOR | GALAPAGOS SAS | 2012-05-10 | — | — | US | disclosed |
| US-8133896-B2 | Pyrimidine derivatives which are antagonist of the vitronectin receptor | GALAPAGOS NV (BE) | 2012-03-13 | — | — | US | disclosed |
| CN-1738817-B | Novel antagonist derivatives of vitronectin receptors, process for their preparation, their use as medicaments and pharmaceutical compositions containing them | Galapagos S.A.S. (FR) | 2011-12-21 | — | — | CN | disclosed |
| EP-0751773-A4 | TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 1997-07-16 | — | — | EP | disclosed |
| EP-0751773-A1 | TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 1997-01-08 | — | — | EP | disclosed |
| US-5464788-A | Stopping labor | MERCK & CO., INC. (US) | 1995-11-07 | — | — | US | disclosed |
| WO-1995025443-A1 | TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1995-09-28 | — | — | WO | disclosed |
| US-5225528-A | Controlling premature labor | MERCK & CO., INC. (US) | 1993-07-06 | — | — | US | disclosed |
| US-5190921-A | Sulfates, sulfonates, phosphates, phosphonates, memory enhancement, neuroleptic agents | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 1993-03-02 | — | — | US | disclosed |
| US-5071836-A | A decapeptide for the treatment of gonadotrophin and steroid-related diseases; inhibits the formation of luteinizing follicle stimulating hormones | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-12-10 | — | — | US | disclosed |
| EP-0444898-A1 | Cyclic hexapeptide oxytocin antagonists | MERCK & CO. INC. (US) | 1991-09-04 | — | — | EP | disclosed |
| US-4420424-A | New peptides and a process for their preparation | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-12-13 | — | — | US | disclosed |
| US-4088537-A | BIOTRANSFORMATION | THE UPJOHN COMPANY (US) | 1978-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115883-A1 | PYRIMIDINE DERIVATIVES WHICH ARE ANTAGONISTS OF THE VITRONECTIN RECEPTOR | P2RY1, P2RY2, P2RX5 | FFAR3 538/4885LCK 2899/4885FYN 1030/4885 |
| US-20120316338-A1 | Methods and Intermediates for the Preparation of Optionally Radio-Labeled Imatinib | ABL1, PDGFRB, PDGFRA | FFAR3 1803/4885LCK 63/4885FYN 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.